Skip to content
Companies

Immunic

Oral drugs for multiple sclerosis and colitis

Raised to date

$200M

of $200M offered across 1 Form D filing

Investors
43
Last filed
Mar 4, 2026

About

Immunic, Inc. is a late-stage clinical biotechnology company focused on developing novel oral therapies for chronic inflammatory, autoimmune, neurologic, and gastrointestinal diseases. The company's primary focus is on its lead drug candidate, vidofludimus calcium, which is in Phase 3 trials for the treatment of multiple sclerosis. Immunic aims to address unmet needs by targeting mechanisms like Nurr1 activation and DHODH inhibition to offer neuroprotective and anti-inflammatory benefits.

The company's lead candidate, vidofludimus calcium, is a first-in-class Nurr1 activator with a multi-mechanism profile, offering neuroprotective, anti-inflammatory, and antiviral effects. This dual-action approach is designed to address neurodegeneration in multiple sclerosis, a key aspect not fully covered by many existing inflammation-focused therapies.

Funding

  • EquityFiled Mar 4, 2026Form D
    $200M/ $200M

Product

Vidofludimus calcium (IMU-838)

Oral Neurologic Therapy

Vidofludimus calcium is the company's lead oral drug candidate, currently in Phase 3 (ENSURE-1 and ENSURE-2) clinical trials for the treatment of relapsing multiple sclerosis (RMS). It has also demonstrated positive activity in Phase 2 trials for progressive MS and ulcerative colitis. The company plans to initiate a Phase 3 trial for primary progressive multiple sclerosis (PPMS) in 2026.

  • Oral administration
  • Acts as a Nurr1 activator, providing neuroprotective effects
  • Functions as a DHODH inhibitor, delivering anti-inflammatory and antiviral activity

Built for

Patients diagnosed with chronic inflammatory and autoimmune diseases, with a specific focus on those with multiple sclerosis (MS).

People on file